Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Joan H. Schiller, David P. Harrington, Chandra Prakash Belani et al. · New England Journal of Medicine · 2002
BACKGROUND: We conducted a randomized study to determine whether any of three chemotherapy regimens was superior to cisplatin and paclitaxel in patients with advanced non-small-cell lung cancer. METHODS: A total of 1207 patients with advanced non-small-cell lung cancer were randomly assigned to a reference regimen of cisplatin and paclitaxel or to one of three experimental regimens: cisplatin and gemcitabine, cisplatin and docetaxel, or carboplatin and paclitaxel. RESULTS: The response rate for all 1155 eligible patients was 19 percent, with a median survival of 7.9 months (95 percent confidence interval, 7.3 to 8.5), a 1-year survival rate of 33 percent (95 percent confidence interval, 30 to 36 percent), and a 2-year survival rate of 11 percent (95 percent confidence interval, 8 to 12 percent). The response rate and survival did not differ significantly between patients assigned to receive cisplatin and paclitaxel and those assigned to receive any of the three experimental regimens. Treatment with cisplatin and gemcitabine was associated with a significantly longer time to the progression of disease than was treatment with cisplatin and paclitaxel but was more likely to cause grade 3, 4, or 5 renal toxicity (in 9 percent of patients, vs. 3 percent of those treated with cisplatin plus paclitaxel). Patients with a performance status of 2 had a significantly lower rate of survival than did those with a performance status of 0 or 1. CONCLUSIONS: None of four chemotherapy regimens offered a significant advantage over the others in the treatment of advanced non-small-cell lung cancer.
Cited by 4,949 works. doi:10.1056/nejmoa011954
Authors
- Joan H. Schiller
- David P. Harrington
- Chandra Prakash Belani
- Corey Jay Langer
- Alan Sandler
- James Edward Krook
- Junming Zhu
- David H. Johnson
References
- Evaluation of survival data and two new rank order statistics arising in its consideration.
- Nonparametric Estimation from Incomplete Observations
- A Multiple Testing Procedure for Clinical Trials
- Analysis of Binary Data
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
- Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
- Analysis of Binary Data (2nd ed.).
- A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
- Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial
- Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?